BriaCell's Bria-IMT Shows Durable Survival, 16.6-Month Median OS in Breast Cancer at ASCO
BCTX is trading near its 52-week low of $2.98 (10% above the low).
Summary
BriaCell presented highly positive clinical data for its Bria-IMT immunotherapy at ASCO 2026, reporting a median overall survival of 16.6 months in Phase 2 patients treated with the Phase 3 regimen. The data also showed 50% 12-month and 25% 24-month overall survival rates for patients initiating checkpoint inhibitor therapy in Cycle 1, which is the Phase 3 study regimen. The treatment demonstrated an excellent safety profile with no unexpected signals. This strong clinical progress is crucial for the small-cap biotech, especially following its recent 10-Q that included a going concern warning and a recent dilutive financing. The ongoing pivotal Phase 3 Bria-ABC study will be key for further validation.
At the time of this announcement, BCTX was trading at $3.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $2.98 to $36.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.